Mesenchymal stem cells (MSCs) are a type of adult stem cell that can be found in many tissues throughout the body, including the bone marrow, fat, and cartilage. These cells have the ability to self-renew and differentiate into a variety of cell types, including osteoblasts (bone cells), chondrocytes (cartilage cells), and adipocytes (fat cells). MSCs were first isolated from the bone marrow in the early 1970s, and since then, they have been the subject of intense scientific research. The potential use of these cells for the treatment of a variety of diseases, including hip arthritis, has been of particular interest. Hip arthritis is a degenerative joint disease that affects millions of people worldwide. It is characterized by the loss of cartilage in the hip joint, resulting in pain, stiffness, and reduced mobility. Current treatment options for hip arthritis include pain relief, weight management, and exercise. In severe cases, joint replacement surgery may be necessary. The use of MSCs for the treatment of hip arthritis is a promising new approach that is currently being investigated. The rationale for using these cells is that they have the ability to regenerate damaged tissue, including cartilage. In animal studies, MSCs have been shown to be effective in reducing the symptoms of arthritis and restoring joint function. A number of clinical trials are currently underway to assess the safety and efficacy of MSC therapy for hip arthritis. The results of these studies will be crucial in determining whether this new treatment option can provide relief for the millions of people suffering from this debilitating disease.
"Mesenchymal Stem Cells injection in hip osteoarthritis - NCBI." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503401/. Accessed 24 Oct. 2022.
"Mesenchymal stem cell therapy in the treatment of hip osteoarthritis." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467400/. Accessed 24 Oct. 2022.
"The human arthritic hip joint is a source of mesenchymal stromal ...." 13 May. 2020, https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-020-03340-z. Accessed 24 Oct. 2022.
The information below is the recommended stem cell therapy protocol for this condition
|Route of Administration